02 maj: Coloplast fortsætter den solide udvikling i andet kvartal og øger..
02 maj: VÆKST PÅ 29 % I 2. KVARTAL - RTX FASTHOLDER FORVENTNINGERNE TIL Å..
02-05-2019 12:09:15

Coloplast announcement no. 04/2019 - Interim Financial Report, H1 2018/19

H1 2018/19

Interim financial report, H1 2018/19

(01 October 2018 - 31 March 2019)             

Solid underlying performance continues in Q2

  • Coloplast delivered 8% organic growth in the second quarter. Year to date organic growth was 8% and reported revenue in DKK was up by 9% to DKK 8,722m.
  • Organic growth rates by business area year to date: Ostomy Care 7%, Continence Care 8%, Interventional Urology 9% and Wound & Skin Care 10%.  
  • Continued strong momentum in Europe with 6% organic growth in the first six months, driven by new product launches including SenSura® Mio Convex, SenSura® Mio Concave and SpeediCath® Flex.
  • Ostomy Care was positively impacted by solid momentum in Europe, US and China but negatively impacted by lower tender activity in Emerging markets in Q2, in particular in Russia.
  • The French reimbursement review in Ostomy Care, Continence Care and Wound Care is still ongoing. Coloplast now expects a final decision during Q3.
  • The Wound Care business delivered 9% organic growth year to date driven by the Biatain® Silicone portfolio in Europe and in particular in the UK and France.
  • The Interventional Urology business delivered 9% organic growth in the first six months, driven by sales and marketing investments in the US.
  • The incremental investments into innovation and sales and marketing initiatives of up to 2% of revenue that were initiated in Q1 are progressing according to plan.
  • EBIT amounted to DKK 2,639m for the first six months, a 10% increase in DKK, corresponding to an EBIT margin of 30% on par with the same period last year. Restructuring costs of DKK 27m were included in the first six months in connection with the reduction of production staff in Denmark.
  • ROIC after tax before special items was 44% in the first six months against 40% in the same period last year.
  • The Board of Directors has resolved that Coloplast will pay a half-year interim dividend of DKK 5.00 per share for a dividend pay-out of DKK 1,062m.

Financial guidance for 2018/19

  • We continue to expect organic revenue growth of ~8% at constant exchange rates and now a reported growth in DKK of ~9% from previously 8-9%.
  • We continue to expect an EBIT margin of 30-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

Capital expenditure is now expected to be DKK ~700m from previously DKK ~750m, and we continue to expect the effective tax rate to be ~23%.

For more information, please contact:

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel. +45 4911 1111

Ellen Bjurgert

Vice President

Investor Relations

Tel. +45 4911 1800 / 4911 3376                       

E-mail dkebj@coloplast.com

Rasmus Sørensen

Senior Manager

Investor Relations

Tel. +45 4911 1800 / 4911 1786

E-mail dkraso@coloplast.com

Press and the media

Dennis Kaysen

Director

Corporate Communications

Tel. +45 4911 2608

E-mail dkdk@coloplast.com

Lina Danstrup

Senior Media Relations Manager

Corporate Communications

Tel. +45 4911 2607

E-mail dklina@coloplast.com

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Business reg. (CVR) no. 69749917

Website

www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2019-05.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment

logo.png

Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 maj
VELO
Så er der lidt at læse på. . Se bla.. Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) ha..
21
23 maj
VELO
Har modtaget data, som viser en stigning i receptal på 20% siden Januar 2019.  
19
20 maj
PNDORA
Paa trods af et godkendt Q1 regnskab, er aktien faldet som en sten. Markedet er ligeglad med Pandora..
17
22 maj
VWS
Vestas secures 44 MW order for V120-2.2 MW turbines with tall tower solution News release from Ves..
16
20 maj
DANSKE
Hører på Radio247 at Jyske Bank er indblandet i momssvindel via et par kunder. Penge ud og ind på en..
15
23 maj
VELO
Kære Nikw. Sagen er kort, at data af konkurence hensyn ikke sendes til højre eller venstre. Man kan ..
13
20 maj
VELO
KEMPEN & CO. tager Velo op til analyse, og sætter kursmaal til 4 kr. 
13
21 maj
VELO
  Igangværende studier vil stille og roligt i højere grad vise, den forbedrede biotilgængelighed og ..
11
24 maj
BAVA
Alle skriver tal, tal, tal og atter tal...   Kik dog på hvorfor stigningerne kommer...Igen igen og i..
10
24 maj
BAVA
Der har været gang i omsætning af BAVA-aktier de sidste dage og jeg kan se der er flere herinde der ..
10

Lars Christensens Verden - Episode 19: The Numbers Game - Tænk som en baseballtræner og find de mest attraktive aktier

24-05-2019 06:00:00
I denne episode er Maj Invests aktiechef Kura Kara og tidligere landholdsspiller og professionel basketballspiller Jens Laulund gæster i studiet til en samtale om, hvordan kvantitative analytiske metoder har vundet indpas i professionel holdsport - særligt i USA - og hvordan disse analysemetoder, der i stigende grad anvendes i  f.eks.baseball og basketball, kan lære os meget om investeringsstrateg..

Snabe køber aktier for lige under 1 mio. kr.

24-05-2019 16:07:03
Bestyrelsesformand i A.P. Møller - Mærsk Jim Hagemann Snabe har spenderet en lille million kr. på køb af aktier i firmaet.Snabe har helt præcist købt 144 stk. A-aktier i firmaet til en kurs på 6925 kr. og en samlet kursværdi af 997.200 kr.Mærsk-aktierne er fredag under pres efter selskabets regnskab for første kvartal, der blev offentliggjort fredag før børsåbningen.Mærsks A-aktie ligger kl. 16 fr..

Amerikansk hedgefund øger shortposition på Abmu til 288 mio.

24-05-2019 15:10:00
Eminence Capital har øget sin shortposition i Ambu og har nu shortet 1,21 pct. af den samlede aktiekapital i biotekselskabet mod tidligere 1,03 pct.Det fremgår fredag eftermiddag af en indberetning til Finanstilsynet. Ændringen i positionen er foretaget torsdag, fremgår det af meddelelsen.At gå kort i en aktie er at spekulere i et kursfald. Det sker ved, at spekulanten låner aktier i et selskab, s..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. maj 2019 02:14:47
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190514.2 - EUROWEB2 - 2019-05-27 02:14:47 - 2019-05-27 02:14:47 - 1 - Website: OKAY